Magnetic Resonance Imaging-Based Prostate-Specific Antigen Density for Prediction of Gleason Score Upgrade in Patients With Low-Risk Prostate Cancer on Initial Biopsy

J Comput Assist Tomogr. 2017 Sep/Oct;41(5):731-736. doi: 10.1097/RCT.0000000000000579.

Abstract

Objective: The aim of this study was to assess the utility of prostate-specific antigen density (PSAD) calculated using magnetic resonance imaging for predicting Gleason score (GS) upgrade in patients with low-risk prostate cancer on biopsy.

Methods: Seventy-three patients were divided into 2 groups according to the concordance between biopsy and prostatectomy GS: group 1 (6/6) and group 2 (6/≥7). Magnetic resonance imaging-based PSAD, prostate volume, prostate-specific antigen (PSA), and age were compared between the 2 groups. Logistic regression and receiver operating characteristic curve analysis were performed.

Results: Gleason score was upgraded in 40 patients. Patients in group 2 had significantly higher PSAD and PSA values and smaller prostate volume than did those in group 1. Prostate-specific antigen density of 0.26 ng/mL per cm or higher, PSA of 7.63 ng/mL or higher, and prostate volume of 25.1 cm or less were related to GS upgrade, with area-under-the-curve values of 0.765, 0.721, and 0.639, respectively.

Conclusions: Magnetic resonance imaging-based PSAD could help in predicting postoperative GS upgrade in patients with low-risk prostate cancer.

MeSH terms

  • Aged
  • Biopsy
  • Humans
  • Magnetic Resonance Imaging*
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Prostate-Specific Antigen / metabolism*
  • Prostatic Neoplasms / diagnostic imaging
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology*
  • Reproducibility of Results

Substances

  • Prostate-Specific Antigen